Rein Therapeutics (RNTX) Amortizatization of Intangibles (2017 - 2026)
Rein Therapeutics (RNTX) posted quarterly Amortizatization of Intangibles of $623000.0 for Q1 2026, up 431.38% quarter-over-quarter from -$188000.0 in Q4 2023.
Rein Therapeutics (RNTX) Amortizatization of Intangibles (2017 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Amortizatization of Intangibles for 8 consecutive years, with $623000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles changed N/A year-over-year to $623000.0; the TTM figure through Mar 2026 stood at $623000.0 (changed N/A YoY), while the FY2023 annual figure was -$32000.0, down 115.38% from the prior year.
- Amortizatization of Intangibles grew to $623000.0 in Q1 2026 per RNTX's latest filing, from -$188000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $623000.0 in Q1 2026 and bottomed at -$188000.0 in Q4 2023.
- Historically, Amortizatization of Intangibles has averaged $88777.8 across 3 years, with a median of $52000.0 in 2023.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 3333.33% in 2023 and fell as far as 252.85% in 2023.
- Rein Therapeutics' Amortizatization of Intangibles stood at $123000.0 in 2022, then tumbled by 252.85% to -$188000.0 in 2023, then soared by 431.38% to $623000.0 in 2026.
- Business Quant data shows RNTX's Amortizatization of Intangibles at $623000.0 in Q1 2026, -$188000.0 in Q4 2023, and $1000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 452,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 452,000.00 |
| Jun 30, 2026 | 452,000.00 |
| Mar 31, 2026 | 623,000.00 |
| Mar 31, 2026 | 623,000.00 |
| Dec 31, 2023 | -188,000.00 |
| Dec 31, 2023 | -188,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 52,000.00 |
| Jun 30, 2023 | 52,000.00 |
| Mar 31, 2023 | 103,000.00 |
| Mar 31, 2023 | 103,000.00 |
| Dec 31, 2022 | 123,000.00 |
| Dec 31, 2022 | 123,000.00 |
| Sep 30, 2022 | 64,000.00 |
| Sep 30, 2022 | 64,000.00 |
| Jun 30, 2022 | 18,000.00 |
| Jun 30, 2022 | 18,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Mar 31, 2022 | 3,000.00 |